InfuSystem (NYSE:INFU - Get Free Report) was upgraded by investment analysts at B. Riley to a "strong-buy" rating in a research note issued on Thursday,Zacks.com reports.
A number of other analysts also recently weighed in on the stock. StockNews.com raised shares of InfuSystem from a "buy" rating to a "strong-buy" rating in a research report on Friday, March 14th. Sidoti upgraded shares of InfuSystem to a "strong-buy" rating in a research report on Tuesday, March 18th.
Check Out Our Latest Report on INFU
InfuSystem Stock Up 2.5%
INFU stock traded up $0.14 during mid-day trading on Thursday, reaching $5.62. The company had a trading volume of 25,685 shares, compared to its average volume of 124,678. The firm has a fifty day simple moving average of $5.27 and a 200 day simple moving average of $7.15. The company has a market capitalization of $118.05 million, a price-to-earnings ratio of 93.63 and a beta of 1.73. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.59 and a current ratio of 1.98. InfuSystem has a fifty-two week low of $4.61 and a fifty-two week high of $9.97.
Institutional Investors Weigh In On InfuSystem
Hedge funds have recently added to or reduced their stakes in the business. Barclays PLC raised its stake in InfuSystem by 300.5% during the third quarter. Barclays PLC now owns 28,597 shares of the company's stock worth $192,000 after buying an additional 21,457 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of InfuSystem by 74.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 15,556 shares of the company's stock valued at $104,000 after buying an additional 6,623 shares in the last quarter. Legato Capital Management LLC bought a new stake in shares of InfuSystem in the 4th quarter worth approximately $85,000. Bank of New York Mellon Corp boosted its position in InfuSystem by 14.3% during the 4th quarter. Bank of New York Mellon Corp now owns 91,219 shares of the company's stock valued at $771,000 after buying an additional 11,436 shares during the period. Finally, First Eagle Investment Management LLC boosted its position in InfuSystem by 25.9% during the 4th quarter. First Eagle Investment Management LLC now owns 908,371 shares of the company's stock valued at $7,676,000 after acquiring an additional 186,668 shares in the last quarter. Institutional investors and hedge funds own 71.13% of the company's stock.
InfuSystem Company Profile
(
Get Free Report)
InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.
Recommended Stories
Before you consider InfuSystem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InfuSystem wasn't on the list.
While InfuSystem currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
